Wed, Aug 15, 2018
Log in

Login to your account

Username *
Password *
Remember Me

Dynamic entrepreneurs and change-makers

METal events range from talks with high-profile thinkers to connecting ideas and collaborations.
Dr. Hyung Kim
on Saturday, 03 March 2018
Hyung Kim
  • Title : Chief Scientific Officer & Co-founder / Director of Academic Urology

  • Company : Onco Therapies / Cedar Sinai Medical Center

  • Bio:

    I am the Director of Academic Urology at Cedar Sinai Medical Center and the Associate Director for Surgical Research at the Samuel Oschin Comprehensive Cancer Center. I am a practicing urologic oncologist treating patients with cancers of the kidney, prostate and bladder. My practice-focus is urologic oncology and minimally invasive (laparoscopic and robotic) surgeries. I was previously practicing in New York, when I was recruited in 2010 by Cedars Sinai to lead their urology program. I became one of the youngest urology chairpersons in the country.

    I am one of only a handful of surgeons in the country that runs a research laboratory. My laboratory is funded by R01 grants from the National Cancer Institute at the National Institute of Health (NIH). These grants are typically awarded to the top 10% of peer-reviewed grant applications submitted by scientists. In 2008, I received the Surgeon-Scientist award from the American Urologic Association, which is a national award given to a single urologist each year.

    Approximately a decade of my laboratory research has resulted in a promising cancer therapy that stimulates the immune system against a large number different cancers. The patent for this therapy has been licensed to Onco-therapies, which is a startup company that I cofoundered in order to translate my discoveries to patient care. We are seeking angel funding for drug manufacturing and clinical trial testing in cancer patients.

Maya metalinternational